NICE rejects omalizumab for asthma in children
Using omalizumab (Xolair) to treat children with persistent allergic asthma does not represent good value for NHS money, NICE has said. …
Asthma drug decision 'nonsensical'
Under-12s to be denied asthma jab… only if they live in England
UK's NICE Rejects Novartis' Xolair Again In Kids Aged 6 To 11
View full post on asthma – Google News